Document Detail

Alterations in phenotypic profiles of peripheral blood cells from patients with human American cutaneous leishmaniasis following treatment with an antimonial drug and a vaccine.
MedLine Citation:
PMID:  19631187     Owner:  NLM     Status:  MEDLINE    
The susceptibility or resistance of a vertebrate host to leishmaniasis is related to the species of Leishmania and to the host immune response of the host. In the present study, the phenotypic profiles of the peripheral blood cells of patients with American cutaneous leishmaniasis (ACL) were evaluated before and after receiving three different therapeutic regimens. The study population comprised 24 patients, living in an ACL-endemic area of Caratinga (MG, Brazil), who had been diagnosed as ACL-positive on the basis of characteristic lesions, the Montenegro skin reactivity test, and/or positive parasitology. Subjects were divided into three groups and received treatment regimens based on (i) the pentavalent antimonial (SbV) N-methyl meglumine antimoniate (Glucantime), (ii) the vaccine Leishvacin, or (iii) SbV in association with the vaccine. Comparative analyses of peripheral mononuclear cells prior to and after treatment revealed that the therapeutic regimens induced no significant differences in the percentages of CD3+ and CD4+ T lymphocytes, CD19+ B lymphocytes, or CD16+ and CD56+ natural killer cells. Additionally, the CD4/CD8 and CD3/CD19 ratios remained unaltered by any of the treatments applied. Most previous studies in the field have focused on the analysis of peripheral blood from ACL patients following in vitro stimulation with either Leishmania antigens or mitogens. The ex vivo cellular immune phenotypic profiles determined in the present study, however, revealed that different ACL treatments did not significantly alter either the immune response exhibited by a patient prior to therapy or the expected cure rate.
Ana Cristina C Botelho; Wilson Mayrink; Rodrigo Correa Oliveira
Related Documents :
10482187 - Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthe...
17909857 - Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-d...
20380487 - Adenovirus vaccine immunotherapy targeting wt1-expressing tumors.
14965367 - Potent antitumor effect elicited by superantigen-linked tumor cells transduced with hea...
8501567 - Long-term survival after edmonston-zagreb measles vaccination in guinea-bissau: increas...
7182947 - Effects and side effects of a new trivalent combined measles-mumps-rubella (mmr) vaccine.
Publication Detail:
Type:  Journal Article     Date:  2009-07-22
Journal Detail:
Title:  Acta tropica     Volume:  112     ISSN:  1873-6254     ISO Abbreviation:  Acta Trop.     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-09-23     Completed Date:  2009-11-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370374     Medline TA:  Acta Trop     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  143-8     Citation Subset:  IM    
Laboratório de Imunologia Celular e Molecular, Centro de Pesquisas René Rachou, FIOCRUZ, 30190-002 Belo Horizonte, MG, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD / analysis
Antimony / therapeutic use*
Antiprotozoal Agents / therapeutic use*
Drug Therapy, Combination
Leishmania / isolation & purification
Leishmaniasis Vaccines / therapeutic use*
Leishmaniasis, Cutaneous / drug therapy*,  immunology*
Leukocytes, Mononuclear / chemistry,  immunology*
Middle Aged
Young Adult
Reg. No./Substance:
0/Antigens, CD; 0/Antiprotozoal Agents; 0/Leishmaniasis Vaccines; 7440-36-0/Antimony

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Acceptability, willing to purchase and use long lasting insecticide treated mosquito nets in Orissa ...
Next Document:  Genetic diversity of ribosomal RNA internal transcribed spacer sequences in Lutzomyia species from a...